Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: HSAQ) is a healthcare-focused blank-check company that completed its initial public offering in 2021 and subsequently entered into a business combination agreement with Orchestra BioMed, Inc., a clinical-stage medical device company developing therapies for cardiovascular disease, including its BackBeat cardiac rhythm management and HF2 hypertension programs. The SPAC was sponsored by Health Sciences Management, a sponsor group with a background in life sciences and medtech investing. The annual report on Form 10-K filed with the SEC on January 25, 2023 reflects the company's status during its de-SPAC transition period, with the merger ultimately completing in early 2023. For comprehensive data on HSAQ's deal timeline, sponsor history, and post-merger performance, create a free account at SpacDesk.